Fosfomycin Calcium Market - By Source , By Form , By Application , By End User , By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.

Fosfomycin Calcium Market Overview:

Fosfomycin Calcium Market size is estimated to reach $485 million by 2030, growing at a CAGR of 6.0% during the forecast period 2024-2030. Fosfomycin calcium is a broad-spectrum antibiotic medication primarily used to treat uncomplicated urinary tract infections (UTIs) in women. It fights bacteria by interfering with their cell wall formation at an early stage. This disrupts their growth and ability to multiply, ultimately killing them. The rise of antibiotic resistance is a major driver for the Fosfomycin Calcium market, as it offers an alternative for treating infections caused by resistant bacteria. The rise of antibiotic-resistant bacteria is a major concern in healthcare. Fosfomycin Calcium's effectiveness against some resistant strains positions it as a valuable alternative treatment. 

Fosfomycin calcium is witnessing increased demand due to its application as an adjuvant in chemotherapy treatments especially with the growing incidence of cancer. According to the World Health Organisation, globally over 35 million new cancer cases are predicted in 2050. The role of fosfomycin in combating bacterial infections during chemotherapy makes it a valuable supportive therapy enhancing patient outcomes by addressing infection risks that arise from compromised immune systems. Additionally, fosfomycin calcium aligns with global antibiotic stewardship programs aimed at curbing antibiotic resistance. These programs advocate for the selective use of antibiotics with broad-spectrum efficacy, such as fosfomycin, which has shown effectiveness against multidrug-resistant bacteria.

Market Snapshot: 

Fosfomycin Calcium Market- Report Coverage:

The “Fosfomycin Calcium Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Fosfomycin Calcium Market.

Impact of Covid and Russia Ukraine War:

• The COVID-19 pandemic handicapped the global market extensively resulting in several challenges most notably, supply chain disruptions, but the pandemic caused an upsurge in the sales of the pharma industry. With increasing number of lifestyle diseases, there was a substantial demand for drugs during the pandemic, particularly diabetes medication. 
• The ongoing Ukraine-Russia conflict's impact on Fosfomycin Calcium is indirect. Disruptions in supply chains due to the conflict led to delays in shipments of these drugs. Additionally, geopolitical tensions affect the manufacturing and distribution of the product, causing fluctuations in market availability, pricing, and international trade dynamics within the industry.

Key Takeaways:

• APAC is the largest Market

Geographically, APAC held the largest share with 42% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. The APAC region faces a higher incidence of bacterial infections, which often require antibiotics like Fosfomycin Calcium. Some APAC countries are major manufacturers and exporters of pharmaceuticals. This contributes to the availability and accessibility of Fosfomycin Calcium in the region. Most of the leading producers of Fosfomycin are located in the APAC region only. India is the source of 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs), as per Invest India. The export of generic drugs is one of India's core strengths. According to India Brand Equity Foundation, the total annual turnover of the Indian Pharmaceutical Industry reached $49.8 billion in FY23 and $41.7 billion in 2021-22.

• By Form, Tablet is the Largest Segment

Tablets are a convenient and portable dosage form. They're easy to store, transport, and take with or without water, making them patient-friendly. Tablets can be precisely manufactured to contain a specific dose of Fosfomycin Calcium, ensuring consistent medication delivery. Compared to other formats like injections or liquids, tablets can be a more cost-effective option to manufacture and distribute. Fosfomycin Calcium for UTIs is often prescribed as a single-dose treatment. Tablets are well-suited for this purpose, as they offer a simple and complete dose in one unit. Tablets are the most widely prescribed dosage form as they are cost-effective, stable, and easy-to-administer. According to the Japan Pharmaceutical Manufacturers Association (JPMA), tablets accounted for 46.5%, followed by injections (13.9%). These two categories made up 60.4% of the total amount of production of pharmaceuticals in 2020 by drug form.

• Urinary Tract Infection is the Largest Segment

Urinary tract infections (UTIs) are extremely common, especially among women. This high prevalence translates to a significant market for UTI treatments. Fosfomycin is a broad-spectrum antibiotic, meaning it targets a wide range of bacteria that can cause UTIs. This makes it a valuable option for treating UTIs caused by susceptible strains, including E. coli, a common culprit. Unlike many other antibiotics that require multiple doses over several days, Fosfomycin Calcium for UTIs often comes as a single-dose treatment. This improves patient compliance and reduces the risk of missed doses or incomplete treatment. According to a report in the research square, In 2019, more than 404.6 million (95% UI 359.4-446.5) individuals had UTIs globally and nearly 236 786 people (198 433 − 259 034) died of UTIs, contributing to 5.2 million (4.5–5.7) DALYs. The age-standardised incidence rate increased from 4 715.0 (4 174.2-5 220.6) per 100 000 population in 1990 to 5 229.3 (4 645.3-5 771.2) per 100 000 population in 2019.

• Growing Pharmaceutical Industry Drives the Market

The pharmaceutical industry is flourishing due to the outbreaks of diseases. With the global burden of diseases growing, there is a need for pharmaceuticals to treat diseases. According to Invest India, the pharmaceutical industry in India is expected to reach $65 billion by 2024 and to $130 billion by 2030. India is a major pharmaceutical exporter, supplying over 200 countries, including meeting 50% of Africa's generic drug needs, 40% of the U.S. demand, and 25% of the UK's demand. Additionally, the growing antibiotic resistant has led to the search for potent compounds and fosfomycin’s ability to treat infections caused by resistant bacteria is invaluable.

• Regulatory Compliance to Hamper the Growth

Regulations govern the information that can be included on the packaging and prescribing information for Fosfomycin Calcium medications. A prime example is the European Medicines Agency's (EMA) 2020 recommendations limiting the use of fosfomycin-containing medications. This restricted the use of intravenous Fosfomycin Calcium to serious infections only. EMA has recommended that fosfomycin medicines given by infusion (drip) into a vein should only be used to treat serious infections when other antibiotic treatments are not suitable. Fosfomycin medicines given by mouth can continue to be used to treat uncomplicated bladder infections in women and adolescent girls. Such regulations can significantly impact market growth in affected regions.

Fosfomycin Calcium Market: Market Share (%) by Geography, 2023

For more details on this report - Request for Sample

Key Market Players: 

The top 10 companies in the Fosfomycin Calcium Market are:

1. Merck KGaA
2. Thermo Fisher Scientific
3. Cayman Chemical Company
4. Actylis
5. Ercros SA
6. Hefei TNJ Chemical Industry Co., Ltd.
7. Shaanxi TNJONE Pharmaceutical Co., Ltd
8. Henan Tianfu Chemical Co., Ltd.
9. Hebei Yanxi Chemical Co., Ltd.
10. Hebei Guanlang Biotechnology Co., Ltd.

Scope of Report: 

For more Lifesciences and Healthcare Market reports, please click here